文献速递白血病造血干细胞移植与细胞治疗

PTPN11突变在JMML诱导多能干细胞造血分化潜能增强中的关键作用

Essential role of PTPN11 mutation in enhanced haematopoietic differentiation potential of induced pluripotent stem cells of juvenile myelomonocytic leukaemia.
PubMed 文献 · Br J Haematol · 2019-06-20

研究从PTPN11 c.226G>A突变的幼年型粒单核细胞白血病(JMML)患者建立突变型与非突变型诱导多能干细胞(iPSC)克隆,在辐照AGM-S3细胞包被并依次或同时添加四种生长因子的培养体系中,突变型iPSC集落生成的CD34+与CD34+CD45+细胞显著多于非突变型集落。锌指核酸酶介导的同源重组纠正PTPN11突变后,CD34+细胞生成降至与双基因野生型JMML iPSC及正常iPSC相似水平;将PTPN11突变导入双基因野生型JMML iPSC则使CD34+细胞生成增至与携带双突变iPSC集落相当的水平。

要点

  • 突变型JMML iPSC集落生成的CD34+与CD34+CD45+细胞显著多于非突变型集落。
  • 非突变型JMML iPSC造血分化潜能相似于或低于健康人iPSC集落。
  • 纠正PTPN11突变使CD34+细胞生成降至双基因野生型及正常iPSC水平。

核心结论

  • PTPN11突变可能是赋予该疾病异常造血分化潜能的最关键异常。

研究设计与样本

  • 从PTPN11 c.226G>A突变JMML患者建立突变型与非突变型iPSC克隆,两种iPSC均符合质量标准。
  • 在辐照AGM-S3细胞包被并依次或同时添加四种生长因子的培养体系中比较造血分化。
  • 采用锌指核酸酶介导的同源重组纠正或导入PTPN11突变。

主要发现

  • 突变型iPSC集落生成的CD34+和CD34+CD45+细胞显著多于非突变型iPSC集落。
  • 非突变型JMML iPSC集落的造血分化潜能相似于或低于健康个体iPSC集落。
  • PTPN11突变与OSBP2 c.389C>T突变共存。
  • 纠正PTPN11突变后CD34+细胞生成减少至与双基因野生型JMML iPSC集落相似水平,且与正常iPSC集落相似。
  • 将PTPN11突变导入双基因野生型JMML iPSC后CD34+细胞生成增加至与携带双突变iPSC集落相当水平。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We established mutated and non-mutated induced pluripotent stem cell (iPSC) clones from a patient with PTPN11 (c.226G>A)-mutated juvenile myelomonocytic leukaemia (JMML). Both types of iPSCs fulfilled the quality criteria. Mutated iPSC colonies generated significantly more CD34+ and CD34+ CD45+ cells compared to non-mutated iPSC colonies in a culture coated with irradiated AGM-S3 cells to which four growth factors were added sequentially or simultaneously. The haematopoietic differentiation potential of non-mutated JMML iPSC colonies was similar to or lower than that of iPSC colonies from a healthy individual. The PTPN11 mutation coexisted with the OSBP2 c.389C>T mutation. Zinc-finger nuclease-mediated homologous recombination revealed that correction of PTPN11 mutation in iPSCs with PTPN11 and OSBP2 mutations resulted in reduced CD34+ cell generation to a level similar to that obtained with JMML iPSC colonies with the wild-type of both genes, and interestingly, to that obtained with normal iPSC colonies. Transduction of the PTPN11 mutation into JMML iPSCs with the wild-type of both genes increased CD34+ cell production to a level comparable to that obtained with JMML iPSC colonies harbouring the two genetic mutations. Thus, PTPN11 mutation may be the most essential abnormality to confer an aberrant haematopoietic differentiation potential in this disorder.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Shigemura T, Matsuda K, Kurata T, et al. Essential role of PTPN11 mutation in enhanced haematopoietic differentiation potential of induced pluripotent stem cells of juvenile myelomonocytic leukaemia. Br J Haematol. 2019. PMID: 31222725. doi:10.1111/bjh.16060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。